ArriVent BioPharma (AVBP) vs Design Therapeutics (DSGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Design Therapeutics (DSGN) has outperformed ArriVent BioPharma (AVBP) over the past year, gaining 8.0% versus a loss of 48.3%. Design Therapeutics is the larger company by market cap ($577.6 million vs $544.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVBP | DSGN |
|---|---|---|
| Share price | $10.52 | $9.02 |
| Market cap | $544.13M | $577.61M |
| 1-day change | -6.57% | -3.22% |
| YTD return | -47.71% | -3.84% |
| 1-year return | -48.30% | +8.02% |
| 5-year return | — | -49.27% |
| EPS (TTM) | $-3.60 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-166.31M | $-69.79M |
| 52-week high | $35.83 | $17.25 |
| 52-week low | $10.33 | $8.21 |
| Distance from 52-week high | -70.64% | -47.71% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +149.05% | +139.14% |
| Average volume | 1.37M | 554.69K |
| Shares outstanding | 51.72M | 64.04M |
| Employees | 77 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DSGN has outperformed AVBP by 56.3 percentage points over the past year.
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees
About Design Therapeutics
DSGN stock →Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
AVBP vs DSGN FAQ
Which is bigger, ArriVent BioPharma or Design Therapeutics?
Design Therapeutics (DSGN) is larger, with a market capitalization of $577.61M compared with $544.13M for ArriVent BioPharma (AVBP).
Which stock has performed better over the past year, AVBP or DSGN?
DSGN returned +8.02% over the past 12 months, compared with -48.30% for AVBP (price return, excluding dividends). Past performance does not predict future results.
Are ArriVent BioPharma and Design Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.